.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
McKinsey
Healthtrust
Covington
Dow
Moodys
Chubb
Express Scripts
Deloitte
QuintilesIMS

Generated: November 21, 2017

DrugPatentWatch Database Preview

Pfizer Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER INC, and what generic alternatives to PFIZER INC drugs are available?

PFIZER INC has eleven approved drugs.

There are twenty-five US patents protecting PFIZER INC drugs on PFIZER INC drugs in the past three years. There is one tentative approval on PFIZER INC drugs.

There are six hundred and twenty-eight patent family members on PFIZER INC drugs in seventy countries and twenty-seven supplementary protection certificates in thirteen countries.

Summary for Pfizer Inc

International Patents:628
US Patents:25
Tradenames:11
Ingredients:11
NDAs:11
Drug Master File Entries: 73
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
TROXYCA ER
naltrexone hydrochloride; oxycodone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL207621-002Aug 19, 2016RXNoNo► Subscribe► SubscribeY ► Subscribe
Pfizer Inc
FRAGMIN
dalteparin sodium
INJECTABLE;SUBCUTANEOUS020287-005Apr 4, 2002RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
TROXYCA ER
naltrexone hydrochloride; oxycodone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL207621-005Aug 19, 2016RXNoNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
QUILLICHEW ER
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-002Dec 4, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Pfizer Inc
QUILLICHEW ER
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-003Dec 4, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Pfizer Inc
QUILLICHEW ER
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-001Dec 4, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Pfizer Inc
TROXYCA ER
naltrexone hydrochloride; oxycodone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL207621-006Aug 19, 2016RXNoNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
QUILLICHEW ER
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-001Dec 4, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Pfizer Inc
XELJANZ XR
tofacitinib citrate
TABLET, EXTENDED RELEASE;ORAL208246-001Feb 23, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pfizer Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-002Mar 27, 1998► Subscribe► Subscribe
Pfizer Inc
FRAGMIN
dalteparin sodium
INJECTABLE;SUBCUTANEOUS020287-003Mar 18, 1996► Subscribe► Subscribe
Pfizer Inc
FRAGMIN
dalteparin sodium
INJECTABLE;SUBCUTANEOUS020287-001Dec 22, 1994► Subscribe► Subscribe
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-001Jun 14, 1996► Subscribe► Subscribe
Pfizer Inc
GEODON
ziprasidone hydrochloride
SUSPENSION;ORAL021483-001Mar 29, 2006► Subscribe► Subscribe
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-003Mar 27, 1998► Subscribe► Subscribe
Pfizer Inc
NICOTROL
nicotine
SPRAY, METERED;NASAL020385-001Mar 22, 1996► Subscribe► Subscribe
Pfizer Inc
GEODON
ziprasidone hydrochloride
SUSPENSION;ORAL021483-001Mar 29, 2006► Subscribe► Subscribe
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-002Jun 14, 1996► Subscribe► Subscribe
Pfizer Inc
FRAGMIN
dalteparin sodium
INJECTABLE;SUBCUTANEOUS020287-004Jan 30, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PFIZER INC drugs

Drugname Dosage Strength Tradename Submissiondate
tofacitinib
Extended-release Tablets11 mg
XELJANZ XR
11/7/2016
varenicline tartrate
Tablets0.5 mg and 1 mg
CHANTIX
5/10/2010
ziprasidone hydrochloride
Capsules20 mg, 40 mg, 60 mg and 80 mg
GEODON
2/7/2005
sildenafil citrate
Tablets25 mg and 50 mg
VIAGRA
11/19/2004
sildenafil citrate
Tablets100 mg
VIAGRA
10/25/2004
irinotecan hydrochloride
Injection20 mg/mL, 2 mL and 5 mL vials
CAMPTOSAR
7/26/2004

Non-Orange Book Patents for Pfizer Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,605,610 Aryl fused azapolycyclic compounds► Subscribe
8,883,217Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,337,890Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,465,765Orally effective methylphenidate extended release powder and aqueous suspension product► Subscribe
6,951,938 Aryl fused azapolycyclic compounds► Subscribe
7,144,882Aryl fused azapolycyclic compounds► Subscribe
8,062,667Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,491,935Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,180,100Methylphenidate extended release chewable tablet► Subscribe
8,956,649Orally effective methylphenidate extended release powder and aqueous suspension product► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pfizer Inc Drugs

Country Document Number Estimated Expiration
Estonia05351► Subscribe
Eurasian Patent Organization199900467► Subscribe
China1195755► Subscribe
Israel194042► Subscribe
Cyprus1113322► Subscribe
Poland341824► Subscribe
South Korea20060111716► Subscribe
Eurasian Patent Organization007251► Subscribe
Australia2002348857► Subscribe
Malaysia127807► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pfizer Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0170012 00212Estonia► SubscribePRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016
C021/2008Ireland► SubscribeSPC021/2008: 20081105, EXPIRES: 20210925
1235830/01Switzerland► SubscribePRODUCT NAME: TOFACITINIB; REGISTRATION NO/DATE: SWISSMEDIC 62630 12.07.2013
2008010,C1044189Lithuania► SubscribePRODUCT NAME: VARENICLINUM TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001 - EU/1/06/360/010, 0060926
1999Austria► SubscribePRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
2017 00030Denmark► SubscribePRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
2008 00031Denmark► Subscribe
C/GB99/004United Kingdom► SubscribePRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
2017 00010Denmark► SubscribePRODUCT NAME: PALBOCICLIB, EVENTUELT I FORM AF EN FARMACEUTISK ACCEPTABEL ESTER ELLER ET FARMACEUTISK ACCEPTABELT SALT, AMID ELLER PRODRUG; REG. NO/DATE: EU/1/16/1147/001-006 20161111
2017 00035Denmark► SubscribePRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Federal Trade Commission
Moodys
Daiichi Sankyo
Medtronic
Fuji
Merck
Johnson and Johnson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot